Drug Interactions between quizartinib and Targretin
This report displays the potential drug interactions for the following 2 drugs:
- quizartinib
- Targretin (bexarotene)
Interactions between your drugs
bexarotene quizartinib
Applies to: Targretin (bexarotene) and quizartinib
Consumer information for this interaction is not currently available.
MONITOR: Coadministration with inducers of CYP450 3A4 may decrease the plasma concentrations of quizartinib and its major circulating active metabolite, AC886. According to the prescribing information, quizartinib is primarily metabolized via oxidation by CYP450 3A4/5 in vitro, and AC886 is formed and metabolized by CYP450 3A4/5. Following coadministration of a single 53 mg dose of quizartinib with efavirenz, a moderate CYP450 3A4 inducer, quizartinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 45% and 90%, respectively, while the Cmax and AUC of AC886 decreased by 68% and 96%, respectively. The interaction has not been studied with other, less potent inducers.
MANAGEMENT: The potential for diminished pharmacologic effects of quizartinib should be considered during coadministration with CYP450 3A4 inducers. Alternative treatments may be required if an interaction is suspected.
References
- "Product Information. Vanflyta (quizartinib)." Daiichi Sankyo, Inc. (2023):
Drug and food interactions
bexarotene food
Applies to: Targretin (bexarotene)
Food helps with the absorption of bexarotene from the gastrointestinal tract into the blood stream. You should take each dose the same time everyday with a meal. Avoid consuming large amounts of grapefruit or grapefruit juice during treatment, since doing so may increase the blood levels of bexarotene. Talk to your doctor or pharmacist if you have any questions or concerns about your medication. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.